[
  {
    "ts": null,
    "headline": "How McKesson’s (MCK) Exclusive PHYRAGO Distribution Could Shape Its Specialty Pharma Growth Trajectory",
    "summary": "Earlier this week, Cycle Pharmaceuticals announced the launch of PHYRAGO, a new oncology therapy for leukemia, developed with Handa Therapeutics and made exclusively available in the US through Onco360® and a specialty distribution network that includes McKesson. This collaboration provides McKesson with a valuable commercial opportunity as an exclusive distributor for a newly introduced specialty oncology product in high-need therapeutic areas. We'll explore how McKesson's participation in...",
    "url": "https://finnhub.io/api/news?id=b5cb87ae3acf4d04112628033869a5272db2f70f3dbe2bfbd6128e8e391020e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760839657,
      "headline": "How McKesson’s (MCK) Exclusive PHYRAGO Distribution Could Shape Its Specialty Pharma Growth Trajectory",
      "id": 137165158,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "COR",
      "source": "Yahoo",
      "summary": "Earlier this week, Cycle Pharmaceuticals announced the launch of PHYRAGO, a new oncology therapy for leukemia, developed with Handa Therapeutics and made exclusively available in the US through Onco360® and a specialty distribution network that includes McKesson. This collaboration provides McKesson with a valuable commercial opportunity as an exclusive distributor for a newly introduced specialty oncology product in high-need therapeutic areas. We'll explore how McKesson's participation in...",
      "url": "https://finnhub.io/api/news?id=b5cb87ae3acf4d04112628033869a5272db2f70f3dbe2bfbd6128e8e391020e2"
    }
  }
]